PT-141 (Bremelanotide)

PT-141 (bremelanotide) is a synthetic cyclic peptide that activates melanocortin receptors in the brain, and it is an approved medicine — the highest evidence tier on this site. The FDA approved it on June 21, 2019 as Vyleesi, an on-demand subcutaneous autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) (Drugs@FDA, NDA 210557).

That approval is also the source of this page's central tension. The label covers one narrow indication — low desire causing distress, in premenopausal women, taken at least 45 minutes before anticipated activity — and explicitly states the drug is not indicated for men, for postmenopausal women, or to enhance sexual performance (Vyleesi label). Gray-market "PT-141," by contrast, is marketed as a unisex libido enhancer for anyone. The molecule is the same; the evidence, the dose verification, and the screening that made it an approved drug are not.

Bremelanotide is an analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural peptide that signals through the melanocortin receptor family. It activates several receptor subtypes nonselectively, with potency ordered MC1R, MC4R, MC3R, MC5R, MC2R (Vyleesi label). The receptor thought to matter for sexual response is MC4R, which is expressed in hypothalamic circuits: in rats, PT-141 triggered erections and activated hypothalamic neurons (measured by c-Fos expression), and it produced erections in nonhuman primates and men (Molinoff et al. 2003).

This makes PT-141 mechanistically unusual: it acts in the central nervous system, upstream of the genital vasculature, rather than on blood flow the way PDE5 inhibitors like sildenafil do. Honest caveat: even after approval, the label states that the mechanism by which bremelanotide improves HSDD "is unknown" — MC4R signaling is the leading hypothesis, not a settled fact. Its MC1R activity, the same receptor targeted by its parent compound melanotan-II for tanning, explains the skin-darkening side effect discussed below. Other peptides studied in sexual-behavior circuits, such as kisspeptin-10 and oxytocin, act on entirely different receptor systems.

The approved indication is specific: acquired, generalized HSDD — low sexual desire that causes marked distress or interpersonal difficulty, not explained by another condition, medication, or relationship problem — in premenopausal women (Vyleesi label). It is one of only two FDA-approved HSDD drugs, alongside the daily oral flibanserin (Addyi), and the only on-demand option.

Online, "PT-141" is sold as lyophilized research powder and marketed for a much wider audience: men seeking erection or libido support, couples, and "wellness" contexts. None of that marketing reflects an approved use. The erectile-dysfunction development program that inspired it was real but was ultimately abandoned — see the research snapshot below — and the label language could not be plainer that the drug is not indicated for men or for performance enhancement. For general context on unregulated peptide products, see what are the risks of peptides.

Because bremelanotide went through full drug approval, its side-effect profile is quantified rather than anecdotal. In the phase 3 program and on the label (DailyMed):

• Nausea in 40% of treated women (vs 1.3% on placebo) — 13% needed anti-nausea medication and 8% discontinued because of it. It is most pronounced after the first dose and improves for most by the second.

• Flushing (20.3%), injection-site reactions (13.2%), headache (11.3%), and vomiting (4.8%).

• A transient blood-pressure rise — up to about 6 mmHg systolic and 3 mmHg diastolic, peaking 2–4 hours after dosing, with heart rate dropping up to 5 beats per minute — normally resolving within 12 hours. Because of this, Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease.

• Focal hyperpigmentation — darkening of the face, gums, or breasts — in 1% of women using up to 8 doses per month, but in 38% of participants dosed daily for 8 days in a separate study. It did not fully resolve in everyone after stopping, and risk is higher with darker skin. This is the MC1R effect inherited from melanotan-II.

• A drug interaction with oral naltrexone: bremelanotide can significantly reduce naltrexone levels, a real problem for people taking it for alcohol or opioid use disorder.

A dedicated ambulatory blood-pressure study found the hemodynamic effect of the approved 1.75 mg dose to be small and short-lived in healthy women — systolic increases of about 3 mmHg over the first four hours, with peaks lasting under 15 minutes (White et al. 2017) — which is reassuring for the screened label population and precisely why the cardiovascular contraindications exist for everyone else.

Bremelanotide is a short-acting, on-demand drug — closer to sildenafil in its usage pattern than to daily peptides. After subcutaneous injection, bioavailability is about 100%, peak levels arrive at roughly 1 hour, and the terminal half-life is about 2.7 hours (range 1.9–4.0), with the peptide broken down by hydrolysis of its amide bonds (Vyleesi label). There is no loading, cycling, or titration concept — each dose is a discrete pharmacological event.

The monthly cap is not arbitrary: hyperpigmentation risk climbs steeply with dosing frequency, and the blood-pressure effect argues against stacking doses. See PT-141 dosing concepts for the full educational breakdown.

The approved formulation is a prefilled 1.75 mg/0.3 mL autoinjector — dose-verified, sterile, and designed for self-administration. Gray-market "PT-141" is typically a lyophilized powder vial for reconstitution, and some vendors sell unapproved nasal sprays — a delivery route that was specifically abandoned during development because of erratic absorption and blood-pressure concerns (White et al. 2017).

Vendors also market combinations — PT-141 with PDE5 inhibitors, or blended with melanotan-II for "tan and libido." No such combination has a label, and combining two agents that each affect blood pressure and nausea multiplies the unknowns rather than the benefits.

Bremelanotide's evidence base has two distinct eras. It began as an erectile-dysfunction candidate: derived from melanotan-II, which produced erections in 8 of 10 men with psychogenic ED in an early crossover study (Wessells et al. 1998), PT-141 showed dose-dependent erectile responses in healthy men and in sildenafil non-responders at subcutaneous doses above 1 mg (Rosen et al. 2004) and significant responses intranasally (Diamond et al. 2004). The intranasal route was then dropped — bioavailability varied too widely, raising blood-pressure risk — and the ED program with it (White et al. 2017).

The second era produced the approval. In RECONNECT — two identical phase 3 trials (n=1,267 randomized) — 24 weeks of as-needed 1.75 mg bremelanotide modestly but significantly improved desire scores (+0.35 integrated on the 1.2–6.0 FSFI desire domain) and reduced desire-related distress (−0.33) versus placebo (Kingsberg et al., Obstet Gynecol 2019). A 52-week open-label extension in 684 women found no new safety signals, with nausea (40.4%) still the dominant side effect (Simon et al. 2019). Note what the numbers say: a real, statistically robust effect whose average size is small — the approval reflects a favorable benefit–risk judgment in a screened population, not a transformative aphrodisiac. See the full research and evidence overview.

For deeper dives on this peptide, see:

• PT-141 (Bremelanotide) benefits and areas of interest
• PT-141 (Bremelanotide) side effects and safety context
• PT-141 (Bremelanotide) dosing concepts (educational)
• PT-141 (Bremelanotide) research and evidence overview

Is PT-141 FDA approved? Yes — bremelanotide was approved on June 21, 2019 as Vyleesi, for acquired, generalized HSDD in premenopausal women (Drugs@FDA). But the approval belongs to the prescription autoinjector, not to research-grade powder sold under the PT-141 name, which is unapproved and unverified.

Does PT-141 work for men? It is not approved for men, and the label says so explicitly. Early trials did show dose-dependent erectile responses in men, including sildenafil non-responders (Rosen et al. 2004), but the ED program was discontinued before any efficacy or safety standard for approval was met. "Showed a signal in abandoned trials" and "works" are different claims.

How is PT-141 different from Viagra? Mechanism and target. Sildenafil is a PDE5 inhibitor that acts on penile blood vessels to support an erection once arousal exists; bremelanotide acts on melanocortin receptors in the brain, upstream of blood flow, with desire as its measured endpoint (Molinoff et al. 2003). They also differ hemodynamically: PDE5 inhibitors tend to lower blood pressure, while bremelanotide transiently raises it.

Is PT-141 the same as melanotan? No, but they are close relatives. Bremelanotide is a derivative of melanotan-II, the tanning peptide that first revealed the erection side effect (Wessells et al. 1998). Bremelanotide became an approved sexual-desire drug; melanotan-II remains an unapproved tanning compound. The shared MC1R activity is why both can darken skin.

What are PT-141's most common side effects? Nausea, by a wide margin — 40% of treated women in trials, versus 1.3% on placebo — followed by flushing (20.3%), injection-site reactions (13.2%), and headache (11.3%). A transient blood-pressure rise and, with repeated use, focal skin darkening are the label's key warnings (Vyleesi label).

How often can Vyleesi be used? The label structures it as one 1.75 mg dose at least 45 minutes before anticipated activity, no more than once per 24 hours and 8 times per month — limits driven by the blood-pressure effect and by hyperpigmentation risk, which rises sharply with frequent dosing (Vyleesi label).